冠心舒通胶囊联合曲美他嗪治疗冠心病心绞痛的效果及安全性分析  

Effect and safety analysis of Guanxin Shutong capsule combined with Trimetazidine in the treatment of coronary heart disease angina pectoris

作　　者：张引侠 郭超 Zhang Yinxia;Guo Chao(Lintong Development Zone Boren Hospital,Xi'an,Shaanxi 710600,China)

机构地区：[1]西安临潼开发区博仁医院,陕西西安710600

出　　处：《首都食品与医药》2024年第22期156-159,共4页Capital Food Medicine

摘　　要：目的 探讨冠心病心绞痛患者联合应用冠心舒通胶囊、曲美他嗪治疗的临床效果与安全性.方法 选取西安临潼开发区博仁医院2021年11月-2023年11月诊治的80例冠心病心绞痛患者为观察对象,按随机数字表法分组原则,将其纳入常规组(应用曲美他嗪治疗,40例)、联合组(应用冠心舒通胶囊+曲美他嗪治疗,40例).连用4周后评估中医证候疗效,比较治疗前后主症与次症积分、心功能[心输出量(CO)、每搏输出量(SV)、左心室舒张末径(LVEDD)、左心室收缩末径(LVESD)]、血液流变学[全血黏度(WBV)、红细胞比容(HCT)、红细胞沉降率(ESR)、纤维蛋白原(FIB)]、炎症因子[超敏C反应蛋白(hs-CRP)、白介素-1(IL-1)、白介素-6(IL-6)、白介素-18(IL-18)],观察有无不良反应.结果 联合组中医证候疗效比常规组高(P<0.05).治疗前,两组主症与次症积分、心功能、血液流变学、炎症因子表达无差异(P>0.05);治疗后,两组主症与次症积分、LVEDD、LVESD、WBV、HCT、ESR、FIB、hs-CRP、IL-1、IL-6、IL-18降低,CO、SV升高,且联合组患者治疗后主症与次症积分、LVEDD、LVESD、WBV、HCT、ESR、FIB、hs-CRP、IL-1、IL-6、IL-18比常规组低,CO、SV比常规组高(P<0.05).联合组患者发生的不良反应与常规组无明显差异(P>0.05).结论 冠心病心绞痛患者联合应用冠心舒通胶囊、曲美他嗪治疗具有确切疗效,能够进一步减轻临床症状,改善血液流变学,减轻炎性反应,促进心功能恢复,且不良反应未增加,具有临床借鉴意义.Objective Observation and exploration of the clinical efficacy and safety of the combined use of Guanxin Shutong Capsules and Trimetazidine in the treatment of coronary heart disease angina pectoris patients.Methods From November 2021 to November 2023,Boren Hospital of Xi'an Lintong Development Zone treated 80 patients with coronary heart disease and angina pectoris.They were randomly divided into a control group(treated with Trimetazidine,40 cases)and a combination group(treated with Guanxin Shutong Capsules and Trimetazidine,40 cases).After 4 weeks of continuous use,evaluate the therapeutic effect of Traditional Chinese Medicine syndromes,compare the main and secondary symptom scores,cardiac function[cardiac output(CO),stroke output(SV),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),hemorheology[whole blood viscosity(WBV),hematocrit(HCT),erythrocyte sedimentation rate(ESR),fibrinogen(FIB)],inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-1(IL-1),interleukin-6(IL-6),interleukin-18(IL-18)]before and after treatment,and observe the presence of inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),[interleukin-1(IL-1),interleukin-6(IL-6),interleukin-18(IL-18)].Adverse reactions.Results The therapeutic effect of Traditional Chinese Medicine syndrome in the combined group was higher than that in the conventional group(P<0.05).Before treatment,there was no difference in the scores of main and secondary symptoms,cardiac function,hemorheology,and expression of inflammatory factors between the two groups(P>0.05);after treatment,the main and secondary symptom scores,LVEDD,LVESD,WBV,HCT,ESR,FIB,hs-CRP,IL-1,IL-6,and IL-18 in both groups decreased,while CO and SV increased.In addition,the main and secondary symptom scores,LVEDD,LVESD,WBV,HCT,ESR,FIB,hs-CRP,IL-1,IL-6,and IL-18 in the combination group were lower than those in the control group,while CO and SV were higher than those in the control group(P<0.05).There was no difference in the i

关 键 词：冠心病 心绞痛 冠心舒通胶囊 曲美他嗪 心功能 血液流变学 炎症因子 

分 类 号：R541.4[医药卫生—心血管疾病]